Well, the existing data do not show that. Patients often stop using GLP-1s within a year for a variety of reasons, including cost, meeting their goal weight or gastrointestinal side effects
It is not a marginal improvement
Our actions today answer that call and remove cost barriers so the value of Wegovy and Ozempic can be realized by more patients
Tracking biomarkers across these systems enables better care 85%+ Muscle mass preserved With guidance, patients preserve lean muscle through targeted protein and strength protocols Most GLP-1 programs fall short Without clinical support Higher risk of losing lean tissue Muscle loss Derail treatment adherence Side effects Weight loss without metabolic health No metabolic tracking Most quit within 6 months Early discontinuation Multi-system intervention Success measured across the body Clinician-led care with ongoing oversight Dosing, tolerance, and response actively managed Decisions guided by biological feedback Biomarkers and symptoms used to protect long-term health Long-term healthspan Designed to support aging, resilience, and metabolic health Clinician-guided GLP-1 treatment Your clinician reviews your medical history and goals to determine eligibility and guide the right treatment choice, including injectable or oral options
Third, as a transitional product for people coming off GLP-1 medications who want to maintain some level of metabolic support
But because GLP-1s reduce a patient's appetite, there needs to be more counseling on the nutritional value of the foods the patients do eat, plus unwinding of maladaptive behaviors developed through various dieting attempts
01585-5/asset/19c5e1a6-3ebc-453e-87c3-a11a7b2d6a64/main.assets/gr1.gif)
